Philadelphia Trust Co. Purchases 4,603 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Philadelphia Trust Co. increased its stake in IQVIA Holdings Inc. by 4.2%, holding approximately 113,275 shares, which constitutes 1.7% of its portfolio.
• An analysis from various firms shows a range of price target adjustments for IQVIA, with estimates varying from $160.00 to $235.00 and a consensus rating of "Moderate Buy."
• IQVIA reported strong Q2 earnings, with an EPS of $2.81, exceeding analysts' expectations and reflecting a 5.3% year-over-year revenue growth.

Philadelphia Trust Co. grew its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 4.2% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 113,275 shares of the medical research company's stock after buying an additional 4,603 shares during the quarter. IQVIA makes up about 1.7% of Philadelphia Trust Co.'s investment portfolio, making the stock its 15th largest holding. Philadelphia Trust Co. owned approximately 0.07% of IQVIA worth $19,970,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Cresset Asset Management LLC lifted its holdings in IQVIA by 8.3% in the 1st quarter. Cresset Asset Management LLC now owns 53,722 shares of the medical research company's stock worth $9,471,000 after purchasing an additional 4,097 shares during the last quarter. American Century Companies Inc. lifted its holdings in IQVIA by 26.8% in the 1st quarter. American Century Companies Inc. now owns 1,438,995 shares of the medical research company's stock worth $253,695,000 after purchasing an additional 304,258 shares during the last quarter. Ethic Inc. lifted its holdings in shares of IQVIA by 8.9% during the first quarter. Ethic Inc. now owns 23,893 shares of the medical research company's stock worth $4,092,000 after buying an additional 1,947 shares during the last quarter. Aberdeen Group plc lifted its holdings in shares of IQVIA by 91.5% during the first quarter. Aberdeen Group plc now owns 137,843 shares of the medical research company's stock worth $23,856,000 after buying an additional 65,878 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of IQVIA by 2.9% during the first quarter. Dimensional Fund Advisors LP now owns 1,428,561 shares of the medical research company's stock worth $251,852,000 after buying an additional 40,699 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on IQV shares. UBS Group upped their price target on IQVIA from $185.00 to $225.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Truist Financial upped their price target on IQVIA from $209.00 to $235.00 and gave the stock a "buy" rating in a report on Wednesday, July 23rd. Mizuho upped their target price on IQVIA from $190.00 to $225.00 and gave the company an "outperform" rating in a research note on Friday, July 25th. Barclays upped their target price on IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a research note on Wednesday, July 23rd. Finally, Redburn Partners set a $188.00 target price on IQVIA in a research note on Friday, May 23rd. Seventeen research analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $228.62.

Insider Buying and Selling at IQVIA

In other news, insider Keriann Cherofsky sold 549 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the sale, the insider owned 2,910 shares in the company, valued at approximately $557,352.30. This represents a 15.87% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Eric Sherbet sold 5,800 shares of the stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $190.05, for a total value of $1,102,290.00. Following the sale, the insider owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by corporate insiders.

IQVIA Price Performance

IQVIA stock traded down $0.2750 during mid-day trading on Wednesday, hitting $192.0750. 587,595 shares of the company were exchanged, compared to its average volume of 1,970,865. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.45. The business has a fifty day moving average of $171.82 and a 200 day moving average of $168.51. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The company has a market capitalization of $32.65 billion, a PE ratio of 27.80, a price-to-earnings-growth ratio of 2.11 and a beta of 1.30.

IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.77 by $0.04. The firm had revenue of $4.02 billion during the quarter, compared to analyst estimates of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%.The business's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the prior year, the company posted $2.64 earnings per share. IQVIA has set its FY 2025 guidance at 11.750-12.050 EPS. As a group, sell-side analysts expect that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.